Shares of Argenx SE jumped on Tuesday after the Dutch biotechnology company reported positive results from a Phase 3 clinical trial evaluating its experimental therapy for autoimmune myositis, a rare muscle-weakening disorder.
The late-stage trial met its primary endpoint, demonstrating statistically significant improvement in patient outcomes compared with placebo, Argenx said in a statement. The company did not disclose detailed efficacy data in its initial announcement, though it noted the results support the potential of efgartigimod, the company’s lead candidate, in treating the condition.
Autoimmune myositis encompasses a group of inflammatory muscle diseases that can lead to severe disability if untreated. Current treatment options are limited and often involve high-dose corticosteroids with significant side effects. Argenx’s therapy targets the neonatal Fc receptor (FcRn), aiming to reduce pathogenic antibody levels in patients.
Argenx plans to submit regulatory filings for efgartigimod in autoimmune myositis to the U.S. Food and Drug Administration and the European Medicines Agency by the end of 2024, pending full data analysis. The company’s shares rose more than 10% in early trading, outpacing broader biotech sector gains.
Analysts at Jefferies noted the trial’s success could position Argenx as a leader in rare disease treatments, potentially expanding its commercial footprint beyond its existing approvals in generalized myasthenia gravis. The firm maintains a buy rating on Argenx shares with a price target of $600, citing the strong clinical data and unmet medical need in autoimmune myositis.
Argenx, headquartered in Breda, Netherlands, specializes in developing antibody-based therapies for severe autoimmune diseases. Its market capitalization exceeds $40 billion, reflecting investor confidence in its pipeline and commercial strategy.
